<DOC>
	<DOCNO>NCT01390350</DOCNO>
	<brief_summary>This multi-center double-blind placebo-controlled study ass efficacy safety canakinumab ( trade name Ilaris® ) , high-affinity monoclonal antibody neutralize IL-1β , patient Schnitzler syndrome . Efficacy assess physician 's global assessment ( combined clinical symptom score ) inflammation marker . Following baseline period 1-4 week , patient randomize receive single s.c. injection either 150 mg canakinumab placebo ( day 0 ) . Treatment response assess day 7 . Patients eligible enter 16-week open-label phase receive canakinumab injection ( 150-300mg , dose depend clinical response day 7 ) upon relapse symptom . Visits investigator 's assessment schedule 4-weekly interval follow day 7 . Overall max . 20 subject Schnitzler syndrome enrol . 1 . Amendment : After successful completion 16-week open-label phase patient eligible enter one-year open-label extension study . During part study patient schedule bi-monthly interval . Canakinumab dose perform upon relapse symptom comparable 16-week open-label phase . 2 . Amendment : After successful completion 1-year open-label study extension patient eligible enter another 3-year open-label extension . Patients schedule 3-month-intervals Canakinumab dosing perform individual basis optimize dose interval ensure constant low disease activity .</brief_summary>
	<brief_title>Ilaris® Effects Schnitzler Syndrome ( ILESCH )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Schnitzler Syndrome</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adults ( 18 year old ) Informed consent sign date Able read , understand willing sign inform consent form abide study procedure SchS diagnosis base diagnostic criterion define Appendix Patients symptomatic Schnitzler syndrome [ SchS ] ( define physician 's global assessment minimum score 8 Creactive protein [ CRP ] &gt; upper limit normal [ ULN ] ) Willing , commit able return clinic visit complete studyrelated procedure , include willingness subcutaneous injection administer qualified person In female childbearing potential : Negative pregnancy test ; female willing use highly effective contraception ( PearlIndex &lt; 1 ) . A woman consider childbearing potential postmenopausal great two year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) Subjects consider eligible , meet follow tuberculosis [ TB ] screen criterion : history latent active TB prior screen , sign symptom suggestive active TB , recent close contact person active TB , negative QuantiFERONTB test screening ( QuantiFERONTB test positive , patient include active TB rule appropriate measurement accord standard care ) No participation clinical trial 4 week participation study Concurrent/ongoing treatment anakinra ( Kineret® ) recent treatment within 48 hour prior day 0 Concurrent/ongoing treatment biologics recent treatment ( less 5 half life ) Concurrent/ongoing treatment immunosuppressive ( e.g . cyclosporine , methotrexate , dapsone others ) within 4 week 5 half life prior day 0 , whichever longer Concurrent/ongoing treatment high dos systemic steroid ( &gt; 20mg prednisolone equivalent ) Evidence recurrent latent systemic infection TB Significant medical condition render patient immunocompromised suitable clinical trial Treatment live ( attenuate ) virus vaccine three month prior day 0 3 month end study Evidence tuberculosis define local guidelines/ local medical practice ( screen ) An abnormal chest radiograph consistent clinical sign prior present tuberculosis infection whether previously treat antituberculosis agent A history listeriosis , active persistent chronic active infection ( ) require treatment parenteral antibiotic , parenteral antiviral , parenteral antifungal within four week prior day 0 Significant concomitant illness would adversely affect subject 's participation evaluation study Evidence current HIV , active hepatitis B , hepatitis C infection serological screen History malignancy within five year prior screen successfully treat nonmetastatic cutaneous , basal , squamous cell carcinoma and/or situ cancer Presence follow laboratory abnormality enrollment visit : creatinine &gt; 2.0 x ULN , WBC &lt; 3000/µl ; platelet count &lt; 100000/µl ; alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] &gt; 3.0 x ULN Lactating female pregnant female Subjects concern compliance protocol procedures Any medical condition , opinion Investigator , would interfere participation study place subject risk History substance abuse ( drug alcohol ) factor ( e.g. , serious psychiatric condition ) within last 5 year could limit subject 's ability comply study procedure Subjects detain officially legally official institute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Schnitzler syndrome</keyword>
	<keyword>autoinflammatory syndrome</keyword>
</DOC>